AMARIN CORP PLC -ADR (AMRN)
US0231112063 - ADR
AMRN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While AMRN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, AMRN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AMRN has reported negative net income.
AMRN had a positive operating cash flow in the past year.
AMRN had negative earnings in 4 of the past 5 years.
In the past 5 years AMRN reported 4 times negative operating cash flow.
1.2 Ratios
AMRN has a better Return On Assets (-7.12%) than 90.77% of its industry peers.
The Return On Equity of AMRN (-10.72%) is better than 90.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.12% | ||
| ROE | -10.72% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-4.55%
ROE(3y)-9.11%
ROE(5y)-6.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 66.72%, AMRN belongs to the top of the industry, outperforming 82.56% of the companies in the same industry.
In the last couple of years the Gross Margin of AMRN has declined.
AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.31%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AMRN has been increased compared to 1 year ago.
Compared to 5 years ago, AMRN has more shares outstanding
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.95, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
AMRN has a Altman-Z score (-0.95) which is in line with its industry peers.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | -0.95 |
ROIC/WACCN/A
WACC7.42%
2.3 Liquidity
AMRN has a Current Ratio of 2.80. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN's Current ratio of 2.80 is on the low side compared to the rest of the industry. AMRN is outperformed by 69.06% of its industry peers.
AMRN has a Quick Ratio of 1.80. This is a normal value and indicates that AMRN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AMRN (1.80) is worse than 77.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
Looking at the last year, AMRN shows a very negative growth in Revenue. The Revenue has decreased by -16.82% in the last year.
AMRN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.01% yearly.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2QN/A
Revenue 1Y (TTM)-16.82%
Revenue growth 3Y-20.64%
Revenue growth 5Y6.01%
Revenue growth Q2Q-17.17%
3.2 Future
AMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.30% yearly.
AMRN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.37% yearly.
EPS Next Y-2%
EPS Next 2Y3.78%
EPS Next 3Y28.49%
EPS Next 5Y38.3%
Revenue Next Year-24.81%
Revenue Next 2Y-11.42%
Revenue Next 3Y0.64%
Revenue Next 5Y15.37%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AMRN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMRN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, AMRN is valued cheaper than 95.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.95 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as AMRN's earnings are expected to grow with 28.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.78%
EPS Next 3Y28.49%
5. Dividend
5.1 Amount
No dividends for AMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMARIN CORP PLC -ADR
NASDAQ:AMRN (4/19/2024, 12:59:09 PM)
0.8848
+0.01 (+1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap355.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.12% | ||
| ROE | -10.72% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-16.82%
Revenue growth 3Y-20.64%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y